Mutual of America Capital Management LLC Invests $4.29 Million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Mutual of America Capital Management LLC bought a new stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 130,454 shares of the company's stock, valued at approximately $4,291,000. Mutual of America Capital Management LLC owned 0.34% of Tarsus Pharmaceuticals at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Quest Partners LLC bought a new stake in Tarsus Pharmaceuticals during the 2nd quarter valued at about $61,000. Canada Pension Plan Investment Board bought a new stake in shares of Tarsus Pharmaceuticals during the second quarter valued at approximately $114,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Tarsus Pharmaceuticals by 33.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company's stock valued at $166,000 after purchasing an additional 1,530 shares during the period. SG Americas Securities LLC grew its stake in Tarsus Pharmaceuticals by 87.5% in the third quarter. SG Americas Securities LLC now owns 7,242 shares of the company's stock worth $238,000 after purchasing an additional 3,379 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its stake in Tarsus Pharmaceuticals by 64.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,317 shares of the company's stock worth $241,000 after purchasing an additional 2,879 shares in the last quarter. Institutional investors own 90.01% of the company's stock.

Analyst Ratings Changes

TARS has been the subject of a number of research analyst reports. The Goldman Sachs Group lifted their target price on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a "neutral" rating in a research report on Friday, November 15th. William Blair upgraded Tarsus Pharmaceuticals to a "strong-buy" rating in a report on Friday, August 30th. Finally, Oppenheimer increased their target price on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the stock an "outperform" rating in a report on Thursday, November 14th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $54.20.

Tarsus Pharmaceuticals Stock Up 4.0 %

Shares of TARS traded up $1.84 during midday trading on Friday, hitting $48.24. 589,006 shares of the company's stock traded hands, compared to its average volume of 727,690. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The stock has a market capitalization of $1.84 billion, a price-to-earnings ratio of -12.18 and a beta of 1.00. Tarsus Pharmaceuticals, Inc. has a 1 year low of $15.60 and a 1 year high of $52.99. The firm's fifty day moving average is $39.00 and its 200-day moving average is $32.86.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.